1. GPCR/G Protein Apoptosis MAPK/ERK Pathway
  2. ICMT Apoptosis Ras
  3. Farnesylthioacetic acid

Farnesylthioacetic acid is a competitive, non-substrate inhibitor of Prenylcysteine α-carboxyl methyltransferase. It acts as a non-substrate competitive inhibitor of Arabidopsis thaliana Prenylcysteine α-carboxyl methyltransferase and blocks methyltransferase activity. Farnesylthioacetic acid does not inhibit protein farnesyltransferase activity in Arabidopsis. It induces Apoptosis. Farnesylthioacetic acid regulates the subcellular localization of Ras protein, reducing the proportion of cytoplasmic Ras protein without disrupting membrane binding. It enhances ABA-induced seed dormancy, delays seed germination, and promotes maximum stomatal closure at lower exogenous ABA concentrations. Farnesylthioacetic acid can be used in studies related to promyelocytic leukemia.

For research use only. We do not sell to patients.

Farnesylthioacetic acid

Farnesylthioacetic acid Chemical Structure

CAS No. : 135784-48-4

Size Price Stock
5 mg Ask For Quote & Lead Time
10 mg Ask For Quote & Lead Time
25 mg Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products

View All Ras Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Farnesylthioacetic acid is a competitive, non-substrate inhibitor of Prenylcysteine α-carboxyl methyltransferase. It acts as a non-substrate competitive inhibitor of Arabidopsis thaliana Prenylcysteine α-carboxyl methyltransferase and blocks methyltransferase activity. Farnesylthioacetic acid does not inhibit protein farnesyltransferase activity in Arabidopsis. It induces Apoptosis. Farnesylthioacetic acid regulates the subcellular localization of Ras protein, reducing the proportion of cytoplasmic Ras protein without disrupting membrane binding. It enhances ABA-induced seed dormancy, delays seed germination, and promotes maximum stomatal closure at lower exogenous ABA concentrations. Farnesylthioacetic acid can be used in studies related to promyelocytic leukemia[1][2].

Cellular Effect
Cell Line Type Value Description References
CHO EC50
90 μM
Compound: 11
Agonist activity at human TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium levels
Agonist activity at human TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium levels
[PMID: 20356305]
In Vitro

Farnesylthioacetic acid (2-25 μM; 8 h-2 days) potently inhibits the growth of promyelocytic leukemia HL-60 cells, achieving complete inhibition at a concentration of 5 μM after 2 days, and induces dose-dependent apoptosis, which is characterized by accumulation of cells in sub-G1 phase, increased annexin V binding, and formation of DNA ladder bands[1].
Farnesylthioacetic acid (10-100 μM; 30 min) potently inhibits methylation of the 20-23 kDa protein in HL-60 cell extracts, with an IC50 of 30 μM, while it exhibits weak or no inhibitory effects on histones of other molecular weights[1].
Farnesylthioacetic acid (10 μM; 8 h) increases the proportion of ras protein in the membrane fraction of promyelocytic leukemia HL-60 cells, while reducing the level of cytoplasmic ras protein, without altering the total abundance of ras protein[1].
Farnesylthioacetic acid (100 μM) exhibits no inhibitory effect on protein farnesyltransferase activity in crude extracts of cultured Arabidopsis thaliana cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[1]

Cell Line: human promyelocytic HL-60 leukemic cells
Concentration: 2 μM; 5 μM; 10 μM; 25 μM
Incubation Time: 8 h; 12 h; 2 days
Result: Inhibited HL-60 cell growth in a dose-dependent manner, with complete inhibition at 5 μM after 2 days.
Induced dose-dependent appearance of a sub-G1 cell population: 16% of cells were in sub-G1 with 5 μM, 26% with 10 μM, and 49% with 25 μM after 8 h.
Increased annexin V-FITC binding in a dose-dependent manner, with early apoptotic cells making up 23% of the population with 2 μM, 22% with 5 μM, and 42% with 10 μM after treatment.
Induced internucleosomal DNA degradation, forming the characteristic apoptotic DNA laddering pattern after incubation with 10 μM for 12 h.

Western Blot Analysis[1]

Cell Line: human promyelocytic HL-60 leukemic cells
Concentration: 10 μM
Incubation Time: 8 h
Result: Did not reduce membrane-associated ras protein levels; instead, increased the proportion of ras in the membrane fraction and decreased the proportion in the cytosolic fraction.
Did not alter total ras protein levels in whole cell lysates, and calmodulin subcellular distribution remained unchanged, confirming fractionation integrity.
Molecular Weight

296.47

Formula

C17H28O2S

CAS No.
Appearance

Viscous Liquid

Color

Colorless to light yellow

SMILES

C/C(C)=C\CC/C(C)=C/CC/C(C)=C/CSCC(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (337.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.3730 mL 16.8651 mL 33.7302 mL
5 mM 0.6746 mL 3.3730 mL 6.7460 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (8.43 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (8.43 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.3730 mL 16.8651 mL 33.7302 mL 84.3256 mL
5 mM 0.6746 mL 3.3730 mL 6.7460 mL 16.8651 mL
10 mM 0.3373 mL 1.6865 mL 3.3730 mL 8.4326 mL
15 mM 0.2249 mL 1.1243 mL 2.2487 mL 5.6217 mL
20 mM 0.1687 mL 0.8433 mL 1.6865 mL 4.2163 mL
25 mM 0.1349 mL 0.6746 mL 1.3492 mL 3.3730 mL
30 mM 0.1124 mL 0.5622 mL 1.1243 mL 2.8109 mL
40 mM 0.0843 mL 0.4216 mL 0.8433 mL 2.1081 mL
50 mM 0.0675 mL 0.3373 mL 0.6746 mL 1.6865 mL
60 mM 0.0562 mL 0.2811 mL 0.5622 mL 1.4054 mL
80 mM 0.0422 mL 0.2108 mL 0.4216 mL 1.0541 mL
100 mM 0.0337 mL 0.1687 mL 0.3373 mL 0.8433 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Farnesylthioacetic acid
Cat. No.:
HY-118563
Quantity:
MCE Japan Authorized Agent: